{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:40:49Z","timestamp":1695555649789},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.medcli.2013.04.041","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T04:40:25Z","timestamp":1372912825000},"page":"175.e1-175.e8","source":"Crossref","is-referenced-by-count":4,"title":["Gu\u00eda de consenso nacionales para el estudio y tratamiento de los pacientes con leucemia linfoc\u00edtica cr\u00f3nica"],"prefix":"10.1016","volume":"141","author":[{"given":"Jos\u00e9 A.","family":"Garc\u00eda Marco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Giraldo Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"L\u00f3pez Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"R\u00edos Herranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Sastre Moral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Jos\u00e9","family":"Terol Caster\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Bosch Albareda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.04.041_bib0005","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM199510193331606","article-title":"Chronic lymphocytic leukemia","volume":"333","author":"Rozman","year":"1995","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2013.04.041_bib0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/annonc\/8.suppl_1.S93","article-title":"B-cell chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy","volume":"8","author":"Montserrat","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.medcli.2009.10.016","article-title":"Leucemia linf\u00e1tica cr\u00f3nica: diagn\u00f3stico y tratamiento","volume":"135","author":"Hern\u00e1ndez","year":"2010","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2013.04.041_bib0020","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.04.041_bib0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10428190802688517","article-title":"Treatment of elderly patients with chronic lymphocytic leukemia","volume":"50","author":"Eichhorst","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2013.04.041_bib0030","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/sj.leu.2404584","article-title":"International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia","volume":"21","author":"Rawstron","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2013.04.041_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11899-009-0041-2","article-title":"Eradicating minimal residual disease in chronic lymphocytic leukemia: Should this be the goal of treatment?","volume":"5","author":"Varghese","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.medcli.2013.04.041_bib0040","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.04.041_bib0045","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","article-title":"Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712","volume":"29","author":"Woyach","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0050","unstructured":"National Comprehensive Cancer Network guidelines [consultado 20 Oct 2011]. Disponible en: www.nccn.org"},{"key":"10.1016\/j.medcli.2013.04.041_bib0055","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0060","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.04.041_bib0065","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","article-title":"Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: Results from the LRF CLL4 trial","volume":"29","author":"Gonzalez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0070","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2013.04.041_bib0080","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1182\/blood-2010-12-323980","article-title":"Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia","volume":"117","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.04.041_bib0085","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2141.2006.06382.x","article-title":"Due to low infection rates no routine antiinfective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy","volume":"136","author":"Eichhorst","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0095","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cncr.22094","article-title":"The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia","volume":"107","author":"Francis","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.medcli.2013.04.041_bib0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/ehm.10.77","article-title":"Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab","volume":"4","author":"Vallejo","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0105","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: Systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2013.04.041_bib0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2141.2001.02882.x","article-title":"Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia","volume":"114","author":"Sinisalo","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/cncr.23561","article-title":"Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: A prospective, randomized trial of safety and immunogenicity","volume":"113","author":"Safdar","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.medcli.2013.04.041_bib0120","article-title":"Rituximab blocks protective serological response to influenza A(H1N1) 2009 vaccination in lymphoma patients during or within six months after treatment","volume":"8","author":"Yri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.04.041_bib0125","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1080\/10428190500472974","article-title":"A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and preemptive therapy with nucleoside analogues","volume":"47","author":"Yagci","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2013.04.041_bib0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.03099.x","article-title":"Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy","volume":"115","author":"Rossi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0135","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3324\/haematol.12955","article-title":"Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes","volume":"93","author":"Vanura","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2013.04.041_bib0140","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","article-title":"Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies","volume":"20","author":"Osterborg","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0145","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2141.2003.04439.x","article-title":"Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production","volume":"122","author":"Cazzola","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10245330400018599","article-title":"Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia","volume":"9","author":"Robak","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.medcli.2013.04.041_bib0155","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1993.11.10.1985","article-title":"Richter's syndrome: A report on 39 patients","volume":"11","author":"Robertson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.04.041_bib0160","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1365-2141.2000.02295.x","article-title":"Allogeneic haematopoietic transplantation for Richter's syndrome","volume":"110","author":"Rodriguez","year":"2000","journal-title":"Br J Haematol"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313003485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313003485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T23:31:24Z","timestamp":1563319884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313003485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0025775313003485"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.04.041","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}